HGH Fragment 176-191

Overview

HGH Fragment 176-191 is not a full hormone but a short fragment corresponding to the C-terminal end of the human growth hormone molecule. Researchers isolated this specific region because it appeared responsible for GH's fat-metabolizing activity, while other regions of the molecule are responsible for GH's growth-promoting and blood-sugar effects.

Proposed Mechanism

Isolates the region of the growth hormone molecule linked to fat metabolism, without the growth-promoting or blood-sugar effects of full-length GH. Studied for its ability to stimulate fat breakdown in animal models.

Research Context

The research rationale is essentially one of isolating a single desired effect from a hormone that normally produces several effects at once. Preclinical studies have focused on whether the fragment retains lipolytic (fat-breakdown) activity on its own, without triggering the tissue-growth or insulin-resistance effects associated with full-length growth hormone.

Evidence Status — Well-documented

Well-documented in preclinical literature. Human outcome data is more limited than for the parent GH molecule.

Most available evidence comes from animal and cell-based (in vitro) studies rather than large human trials. This is a common pattern for a “fragment” peptide — the underlying biological hypothesis is well-articulated in the literature, but confirmation in human subjects at meaningful scale is comparatively limited.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.